T2DM and NAFLD patients benefit from the SGLT-2 inhibitor class because it inhibits the renal ability to reabsorb filtered glucose and so improves glycemic management, body weight, and blood pressure [11]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.